Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
Lin Zhang, Bo Hao, Zhihua Geng, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 66

Showing 26-50 of 66 citing articles:

Type 1 diabetes complicated by immune myocarditis induced by toripalimab: A case report
Chen Shui-qing, Ying Li, Gu Xiaoji, et al.
International Journal of Diabetes in Developing Countries (2025)
Closed Access
Liver Transplantation for Non-Hepatocellular Carcinoma: Role of Immune Checkpoint Inhibitors
Pegah Bahrami, Mohammad Al Zein, Ali H. Eid, et al.
Journal of Clinical and Experimental Hepatology (2025), pp. 102558-102558
Closed Access
A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer
Mingzhen Zhou, Yuncheng Jin, Sihui Zhu, et al.
Clinical & Translational Immunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 3
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 5, pp. 2949-2970
Open Access | Times Cited: 3
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
Bixia Tang, Yu Chen, Yu Jiang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 10, pp. e009662-e009662
Open Access | Times Cited: 3
Generation, secretion and degradation of cancer immunotherapy target PD-L1
Dandan Shen, Ya‐Ping Bi, Jing‐Ru Pang, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 8
Open Access | Times Cited: 14
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Víctor Albarrán-Artahona, Juan Carlos Laguna, Teresa Gorría, et al.
Diagnostics (2022) Vol. 12, Iss. 9, pp. 2091-2091
Open Access | Times Cited: 14
Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
Zhenyu Wen, Junxiao Wang, Bo Tu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 20, pp. 20311-20320
Open Access | Times Cited: 7
Primary pure large cell neuroendocrine carcinoma of the urinary bladder: a case report and literature review
Zhenpeng Sun, Xin Liang, Changcun Zhang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Impact of Epstein Barr Virus Infection on Treatment Opportunities in Patients with Nasopharyngeal Cancer
Francesco Perri, Francesco Sabbatino, Alessandro Ottaiano, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1626-1626
Open Access | Times Cited: 6
Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial
Ke Cheng, M Kellis, Wanrui Lv, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
Dimitrios C. Ziogas, Anastasios Martinos, Dioni‐Pinelopi Petsiou, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 2873-2873
Open Access | Times Cited: 8
Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial
Xiangwei Yang, Shiqiang Zhang, Yajiao Cui, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
Gengwei Huo, Wenjie Liu, Shuo Kang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study
Shuyang Zhang, Lu Yang, Yaning Yang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 19, pp. 19438-19448
Open Access | Times Cited: 4
Production of Monoclonal Antibodies for Therapeutic Purposes: Applications, Techniques, and Improvement
Ziqi Ding, Yongqi Huang
(2024)
Open Access | Times Cited: 1
Efficacy and safety of Toliparibumab for the treatment of non-small cell lung cancer: a systematic review and meta-analysis
Yihao Liu, Liang Yu, Zhixuan Duan, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
Jia Zhong, Kailun Fei, Lin Wu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
Tannaz Dehghani, Alireza Shahrjerdi, Mohammad Saeed Kahrizi, et al.
Pathology - Research and Practice (2023) Vol. 246, pp. 154470-154470
Closed Access | Times Cited: 3
Use of monoclonal antibodies in cancer immunotherapy: types and mechanisms of action
Paola Damián-Blanco, Selene Ahuexoteco-Sánchez, Adrián A. Carbajal-Gallardo, et al.
Boletín Médico del Hospital Infantil de México (2023) Vol. 80, Iss. 3
Open Access | Times Cited: 3
Successful treatment of metastatic vulvar malignant melanoma with toripalimab: A rare case report and review of the literature
Yihui Li, Yang Zhou, Guang-Ju Zhang, et al.
Medicine (2022) Vol. 101, Iss. 36, pp. e30239-e30239
Open Access | Times Cited: 4
Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
Hao Wang, Yunchun Long, Yuan Xu, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 2
Clinical outcomes and immunological evaluation of toripalimab combination for cancer treatment: A systematic review and meta-analysis of randomized controlled trials
Jing Li, Haiyan Zhang, Hongda Zhu, et al.
International Immunopharmacology (2023) Vol. 125, pp. 111176-111176
Closed Access | Times Cited: 2
Metastatic Germ Cell Tumor Showing a Durable Response to the Anti-PD-1 Antibody Toripalimab
Ruiqi Wang, Wanning Wang, Wenlong Zhang, et al.
Immunotherapy (2023) Vol. 15, Iss. 8, pp. 565-572
Closed Access | Times Cited: 1
Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer
Huijie Qi, Wenxin Zhang, Bicui Chen, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 3, pp. 441-453
Closed Access

Scroll to top